Price (delayed)
$5.7
Market cap
$36.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.46
Enterprise value
$47.76M
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new
There are no recent dividends present for CLNN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.